Search
인용 및 참조 문헌 (1)
Invitrogen™
LentiArray™ CRISPR Positive Control Lentivirus, human HPRT, with GFP
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray CRISPR Positive Control자세히 알아보기
Have Questions?
보기 방식 변경
| 카탈로그 번호 | 수량 |
|---|---|
| A32060 | 100 μL |
| A32830 | 1 mL |
카탈로그 번호 A32060
제품 가격(KRW)
726,000
Online offer
Ends: 31-Dec-2025
806,000할인액 80,000 (10%)
Each
수량:
100 μL
제품 가격(KRW)
726,000
Online offer
Ends: 31-Dec-2025
806,000할인액 80,000 (10%)
Each
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray CRISPR Positive Control Lentivirus gRNA against HPRT is a highly efficient gRNA validated in multiple human cell lines that has achieved editing efficiencies of greater than 80%. It can be used to rapidly determine ideal delivery conditions in order to achieve maximum editing efficiency in your cell model of choice. This construct also expresses emGFP to provide a visual readout of successful transduction that can be used in determining Multiplicity of Infection (MOI).
For Research Use Only. Not for use in diagnostic procedures.
사양
배달 유형Lentiviral
용도(애플리케이션)Genome Editing
제품라인LentiArray
제품 유형gRNA
프로모터U6
수량100 μL
배송 조건Dry Ice
제어 유형Positive Control
형식Tube
RNAi TypegRNA
종Human
Unit SizeEach
구성 및 보관
1 x 100 μL. Store (at -68°C to -85°C.)
인용 및 참조 문헌 (1)
인용 및 참조 문헌
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific